CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Blood
المؤلفون الرئيسيون: Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Hematology 2021
الموضوعات:
Clinical Trials and Observations
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085484/
https://ncbi.nlm.nih.gov/pubmed/33512414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009432
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة